Back to News
Market Impact: 0.15
Taiho Oncology and Taiho Pharmaceutical to Present Data from AZTOUND Trial Evaluating Oral Azacitidine and Cedazuridine in Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia at the 68th American Society of Hematology Annual Meeting
Source: Business Wire
Healthcare & Biotech
Data from the AZTOUND trial evaluating oral azacitidine and cedazuridine in patients with MDS or CMML will be presented at the 68th ASH Annual Meeting. The article provides no trial results or efficacy figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- CVS Plans to Break Up $117 Billion Healthcare Conglomerate
- How Abdul El-Sayed would build Medicare for All, from a wealth tax to a Fed-style governing board
- BillionToOne SVP John ten Bosch sells $320,723 in stock
- Novo raises full-year outlook as Wegovy sales impress
- Sight Sciences earnings missed by $0.48, revenue topped estimates
- Novo CEO Doustdar 'Very Optimistic' About CagriSema